Abhishek Srivastava
Keine laufenden Positionen mehr
Vermögen: 145 $ am 31.03.2024
Profil
Abhishek Srivastava worked as the Vice President-Cell Therapy Development at Athenex, Inc. He then served as the Vice President-Technical Operations at Alaunos Therapeutics, Inc. Dr. Srivastava holds a doctorate degree from the University of Louisville School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
15.03.2023 | 80 ( 0,00% ) | 145 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Abhishek Srivastava
Unternehmen | Position | Ende |
---|---|---|
ALAUNOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.10.2023 |
ATHENEXPAR | Corporate Officer/Principal | - |
Ausbildung von Abhishek Srivastava
University of Louisville School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ALAUNOS THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Athenex, Inc.
Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |